000309981 001__ 309981
000309981 005__ 20260220160020.0
000309981 0247_ $$2doi$$a10.1002/1878-0261.70227
000309981 0247_ $$2pmid$$apmid:41714116
000309981 0247_ $$2ISSN$$a1574-7891
000309981 0247_ $$2ISSN$$a1878-0261
000309981 037__ $$aDKFZ-2026-00407
000309981 041__ $$aEnglish
000309981 082__ $$a610
000309981 1001_ $$00009-0005-6038-2914$$aBielesch, Sophia$$b0
000309981 245__ $$aKeratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high-grade serous ovarian cancer.
000309981 260__ $$aHoboken, NJ$$bJohn Wiley & Sons, Inc.$$c2026
000309981 3367_ $$2DRIVER$$aarticle
000309981 3367_ $$2DataCite$$aOutput Types/Journal article
000309981 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1771599605_3240618
000309981 3367_ $$2BibTeX$$aARTICLE
000309981 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309981 3367_ $$00$$2EndNote$$aJournal Article
000309981 500__ $$aepub
000309981 520__ $$aHigh-grade serous ovarian cancer (HGSOC) is the most prevalent and lethal subtype of epithelial ovarian cancer (EOC), characterised by extensive peritoneal metastasis. The intermediate filament keratin 19 (KRT19) has been linked to tumour progression and chemoresistance in various cancers. However, its role varies across tumour types and remains unclear for HGSOC. We evaluated KRT19 protein expression in 199 HGSOC patients and correlated findings with clinical outcomes. In vitro, we assessed the effects of KRT19 on tumour-associated mechanisms, including proliferation, migration, adhesion, and spheroid formation. A xenograft mouse model was used to assess tumour burden in vivo. Publicly available datasets enabled in silico validation. KRT19 was significantly overexpressed in HGSOC, and high expression was associated with reduced overall survival. In vivo, KRT19-overexpression increased peritoneal tumour burden. In vitro and ex vivo, KRT19 induced a hybrid epithelial phenotype through enhanced epithelial-mesenchymal plasticity (EMP), promoting adhesion, migration, and spheroid integrity, thereby potentially supporting metastatic processes. Further, KRT19 could contribute to paclitaxel resistance. Altogether, KRT19 represents a potential independent prognostic marker and therapeutic target to inhibit metastatic dissemination.
000309981 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000309981 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309981 650_7 $$2Other$$achemoresistance
000309981 650_7 $$2Other$$aepithelial–mesenchymal plasticity
000309981 650_7 $$2Other$$akeratin 19
000309981 650_7 $$2Other$$aovarian cancer
000309981 7001_ $$aVogel, Isabel$$b1
000309981 7001_ $$aNokodian, Sina$$b2
000309981 7001_ $$aMoeller, Johanna$$b3
000309981 7001_ $$aBlechschmidt, Antonia$$b4
000309981 7001_ $$aHecht, Vicky$$b5
000309981 7001_ $$aKuentzel, Vanessa$$b6
000309981 7001_ $$aThiedig, Katharina$$b7
000309981 7001_ $$aSchwab, Melissa$$b8
000309981 7001_ $$00000-0001-7678-7653$$aSchilling, Oliver$$b9
000309981 7001_ $$0P:(DE-HGF)0$$aBronger, Holger$$b10
000309981 7001_ $$aKiechle, Marion$$b11
000309981 7001_ $$aMagdolen, Viktor$$b12
000309981 7001_ $$0P:(DE-HGF)0$$aDreyer, Tobias$$b13
000309981 773__ $$0PERI:(DE-600)2322586-5$$a10.1002/1878-0261.70227$$gp. 1878-0261.70227$$pnn$$tMolecular oncology$$vnn$$x1574-7891$$y2026
000309981 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000309981 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000309981 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000309981 9141_ $$y2026
000309981 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-07$$wger
000309981 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000309981 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000309981 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:04:26Z
000309981 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:04:26Z
000309981 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2024-08-08T17:04:26Z
000309981 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-08-08T17:04:26Z
000309981 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000309981 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
000309981 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000309981 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
000309981 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000309981 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000309981 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL ONCOL : 2022$$d2025-01-07
000309981 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000309981 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000309981 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOL ONCOL : 2022$$d2025-01-07
000309981 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-07
000309981 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-07
000309981 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x0
000309981 980__ $$ajournal
000309981 980__ $$aVDB
000309981 980__ $$aI:(DE-He78)MU01-20160331
000309981 980__ $$aUNRESTRICTED